Search

The effects of fish oil (FO) supplementation on glycaemic control are unclear, and positive effects may occur only when the phospholipid content of tissue membranes exceeds 14 % asn-3 PUFA. Subjects (n36, thirty-three completed) were paired based on metabolic parameters and allocated into a parallel double-blind randomised trial with one of each pair offered daily either 6 g of FO (3·9 gn-3 PUFA) or 6 g of maize oil (MO) for 9 months. Hyperinsulinaemic–euglycaemic–euaminoacidaemic (HIEGEAA) clamps (with [6,62H2glucose]) were performed at the start and end of the intervention. Endogenous glucose production (EGP) and whole-body protein turnover (WBPT) were each measured after an overnight fast. The primary outcome involved the effect of oil type on insulin sensitivity related to glycaemic control. The secondary outcome involved the effect of oil type on WBPT. Subjects on FO (n16) had increased erythrocyten-3 PUFA concentrations >14 %, whereas subjects on MO (n17) had unalteredn-3 PUFA concentrations at 9 %. Type of oil had no effect on fasting EGP, insulin sensitivity or total glucose disposal during the HIEGEAA clamp. In contrast, under insulin-stimulated conditions, total protein disposal (P=0·007) and endogenous WBPT (P=0·001) were both increased with FO. In an associated pilot study (n4, three completed), althoughn-3 PUFA in erythrocyte membranes increased to >14 % with the FO supplement, the enrichment in muscle membranes remained lower (8 %;P

This study investigated the impact of either type 2 diabetes or obesity, separately or in combination, on the absolute amounts of microparticles (MP) and the pathways by which these are associated with either condition. The concentrations of circulating MP derived from platelets (PMP), leukocytes (LMP) and monocytes (MMP), together with their specific activation markers, were compared in 30 subjects who were characterised across 4 cohorts as obese or type 2 diabetes. The subjects with type 2 diabetes had elevated concentrations of total PMP (P = 0.003), and PMP that were fibrinogen-positive (P = 0.04), tissue factor-positive (P

Aims In the UK, lifestyle intervention is first-line management in Type 2 diabetes. It is unclear what type of diet is most efficacious for improving glycaemic control. This study investigated the effects of an oat-enriched diet on glycaemic control, postprandial glycaemia, inflammation and oxidative stress compared with standard dietary advice. Methods In a randomized crossover design, 27 volunteers with Type 2 diabetes, managed on diet and lifestyle only, were observed for two consecutive 8-week periods following either the oat-enriched diet or re-enforced standard dietary advice. Volunteers attended at baseline (habitual intake) and 8 and 16 weeks. Measurements included basic clinical measurements and fasted and postprandial (3-h) glucose and insulin in response to a healthy test meal. Markers of inflammation and oxidative stress, including high-sensitivity C-reactive protein, interleukin 6, interleukin 18, tumour necrosis factor-alpha, adiponectin, thiobarbituric acid reactive substances, oxygen radical antioxidant capacity, oxidized LDL and urinary isoprostanes, were also measured at fasting and in the postprandial period. Results There were no diet-related effects on glycaemic control or glycaemic or insulinaemic responses to the test meal. Total cholesterol (5.1 ± 1.0 vs. 4.9 ± 0.8 mmol/l, P = 0.019) concentrations declined following the oat-enriched diet compared with standard dietary advice. There was a postprandial decline in adiponectin concentration (P = 0.009), but no effect of dietary intervention. None of the measures of oxidative stress or inflammation were altered by the oat-enriched diet compared with standard dietary advice. Conclusion The oat-enriched diet had a modest impact on lipid lowering, but did not impact on oxidative stress or inflammation in these volunteers with Type 2 diabetes.

A recent Cochrane review concluded that low glycaemic index (GI) diets are beneficial in glycaemic control for patients with type 2 diabetes mellitus (T2DM). There are limited UK data regarding the dietary GI in free-living adults with and without T2DM. We measured the energy and macronutrient intake and the dietary GI in a group (n = 19) of individuals with diet controlled T2DM and a group (n = 19) without diabetes, matched for age, BMI and gender. Subjects completed a three-day weighed dietary record. Patients with T2DM consumed more daily portions of wholegrains (2.3 vs. 1.1, P = 0.003), more dietary fibre (32.1 vs. 20.9 g, P < 0.001) and had a lower diet GI (53.5 vs. 57.7, P = 0.009) than subjects without T2DM. Both groups had elevated fat and salt intake and low fruit and vegetable intake, relative to current UK recommendations.CONCLUSIONS:Patients with T2DM may already consume a lower GI diet than the general population but further efforts are needed to reduce dietary GI and achieve other nutrient targets.

Diabetic ketoacidosis (DKA) is a common diabetic emergency often managed by general physicians. However, in contrast to its management in children, there was no national guideline/protocol for adults until the recent national protocol was issued for use throughout Scotland. This national protocol was developed from the audit activity described in this article. A prospective audit of the management of DKA and local protocol adherence was carried out at Raigmore Hospital, Inverness (April 2000 to March 2001). This showed deficiencies in the management of DKA with delay in intravenous fluid and insulin administration, and laboratory monitoring being undertaken less frequently than recommended by local guidelines. In addition, 14 DKA management protocols from 17 Scottish trusts were reviewed. The rate and volume of fluid replacement varied slightly between the trusts. There was general agreement within protocols on laboratory monitoring, potassium replacement, insulin administration and bicarbonate usage. The audit showed that there was scope for improvement in the management of DKA and that there were sufficient similarities in protocols used throughout Scotland to allow collaboration on a national protocol. It is anticipated that this will serve to enhance the profile of guidelines and facilitate standardisation and therefore improvement in patient care. Copyright © 2007 John Wiley & Sons.

Post-prandial hyperglycaemia is predictive of cardiovascular disease risk. Therefore, the International Diabetes Federation (IDF) recommends that 2-hour post-meal glucose should not exceed 7.8mmol/L. There are limited data regarding the extent of post-prandial hyperglycaemia in those with well-controlled type 2 diabetes and how this relates to HbA1c values. Twenty-nine volunteers with diet-controlled type 2 diabetes were recruited (mean HbA1c 50mmol/mol [6.7%], SD 6.5 [0.6]); mean age 62 years [SD 5.8]; mean BMI 31.9kg/m2 [SD 5.3]), and underwent a three-day period of continuous glucose monitoring (CGMS) at home. Compared with volunteers with an HbA1c >48mmol/mol (6.5%), those with an HbA1c ≤48mmol/mol (6.5%) – mean HbA1c 54 (7.1%) vs 44.9mmol/mol (6.3%), p 8mmol/L (703.1 vs 338.5 min, p=0.01). HbA1c showed reasonable correlation with time spent with glucose >8mmol/L (r2=0.48, p

Inflammatory status can increase the risk of adverse cardiovascular events linked to platelet activity and involvement of microparticles (MP) released from platelets (PMP), leukocytes (LMP), and monocytes (MMP). These MP carry host cell-derived antigens that may act as markers of metabolic health. Subjects newly diagnosed with type 2 diabetes are offered appropriate standard dietary advice (SDA) but this may not be optimal as specific inclusion of other nutrients, such as oats, may add benefit. The effectiveness of such interventions can be tested by examination of MP activation markers.Subjects (n = 22) with type 2 diabetes participated in a randomized cross-over trial involving 8 wk interventions with either an oat-enriched diet (OAT) or following reinforced SDA. Responses were also compared with preintervention habitual (HAB) intake. OAT reduced the concentrations and proportions of fibrinogen- and tissue factor-related PMP and MMP_11b. The main effect of SDA was to reduce fibrinogen-activated PMP. Regardless of chronic intake, a healthy test meal led to postprandial declines in total PMP as well as tissue factor-, fibrinogen-, and P-selectin-positive PMP.OAT improved risk factors assessed by MP status, even in subjects with type 2 diabetes already well-controlled by diet and life-style alone.

Background Antithyroid drugs are widely used in the therapy of hyperthyroidism. There are wide variations in the dose, regimen or duration of treatment used by health professionals. Objectives To assess the effects of dose, regimen and duration of antithyroid drug therapy for Graves' hyperthyroidism. Search strategy We searched the Cochrane Central Register of Controlled Trials (Central), MEDLINE, EMBASE, BIOSIS, CINAHL, HEALTHSTAR, Current Controlled Trials and reference lists. We contacted investigators and hand searched conference abstracts. Most recent search: July 2004. Selection criteria Randomised and quasi-randomised trials of antithyroid medication for Graves' hyperthyroidism were used. Data collection and analysis Trial allocation to included, excluded and awaiting assessment categories was made by consensus. Two reviewers independently extracted data and assessed trial quality. Pooling of data for primary outcomes, and select exploratory analyses were undertaken. Main results Twenty-three randomised trials involving 3115 participants were included. Overall the quality of trials as reported was poor; specifically in terms of allocation concealment, assessor blinding and loss to follow-up. Four trials examined the effect of duration of therapy on relapse rates of Graves' hyperthyroidism. In one trial using the Titration regimen, longer duration therapy (18 months) had significantly fewer relapses (37% versus 58%) than six month therapy (Odds ratio (OR) 0.42, 95% confidence interval (CI) 0.18 to 0.96). In one quasi-randomised trial using the Block-Replace regimen, there was no significant difference between the six and 12 month (relapses rates 41% versus 35%) arms of the study. Extending the duration of therapy to over 18 months was not associated with improved relapse rates (Peto OR 0.75, 95% CI 0.39 to 1.43). Twelve trials examined the effect of Block-Replace versus Titration regimen. The relapse rates were similar in both groups at 51% in the Block-Replace group and 54% in the Titration group (Peto OR 0.86, 95% CI 0.68 to 1.08). Participants reporting rashes (10% versus 5%) and withdrawing due to side effects (16% versus 9%) were significantly higher in the Block-Replace group compared to the Titration group respectively. Three studies considered the addition of thyroxine with continued low dose antithyroid therapy after initial therapy with antithyroid drugs. There was significant heterogeneity between the studies and the difference between the two groups were not significant (Odds ratio 0.58, 95% CI 0.05 to 6.21). Four studies considered the addition of thyroxine alone after initial therapy with antithyroid drugs. There was no significant difference in the relapse rates between the groups after 12 months follow-up with relapse rates being 31% (88/282) with thyroxine and 29% (82/284) with placebo (Peto OR 1.15, 95% CI 0.79 to 1.67). Authors' conclusions The evidence (based on four studies) suggests that the optimal duration of antithyroid drug therapy for the Titration regimen is 12 to 18 months. The six month Block-Replace regimen was found to be as effective as the 12 month treatment in one quasi-randomised study. The Titration (low dose) regimen had fewer adverse effects than the Block-Replace (high dose) regimen and was no less effective in trials (based on 12 trials) of equal duration. Continued thyroxine treatment following initial antithyroid therapy does not appear to provide any benefit in terms of recurrence of hyperthyroidism. The incidence of hypothyroidism was not reported and there were no deaths reported in the study populations.